Literature DB >> 20626744

Biochemical aspects of X-linked adrenoleukodystrophy.

Stephan Kemp1, Ronald Wanders.   

Abstract

X-linked adrenoleukodystrophy (X-ALD) is the most common peroxisomal disorder. The disease is characterized by the accumulation of very long-chain fatty acids (VLCFA; >C22) in plasma and tissues. X-ALD is caused by mutations in the ABCD1 gene encoding ALDP, an adenosine triphosphate (ATP)-binding-cassette (ABC) transporter located in the peroxisomal membrane. In this paper, we describe the current knowledge on the function of ALDP, its role in peroxisomal VLCFA beta-oxidation and the consequences of a defect in ALDP on VLCFA metabolism. Furthermore, we pay special attention to the role of the VLCFA elongation system in VLCFA homeostasis, with elongation of very long-chain fatty acids like-1 (ELOVL1) as key player, and its relevance to X-ALD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20626744     DOI: 10.1111/j.1750-3639.2010.00391.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  33 in total

1.  Clinical utility gene card for: adrenoleukodystrophy.

Authors:  Ernst Krasemann; Stephan Kemp; Andreas Gal
Journal:  Eur J Hum Genet       Date:  2011-11-09       Impact factor: 4.246

2.  Clinical reasoning: a 56-year-old man with progressive spasticity.

Authors:  Radhika Dhamija; Gerald V Raymond; Ralitza Gavrilova
Journal:  Neurology       Date:  2013-02-26       Impact factor: 9.910

3.  A zebrafish model of X-linked adrenoleukodystrophy recapitulates key disease features and demonstrates a developmental requirement for abcd1 in oligodendrocyte patterning and myelination.

Authors:  Lauren R Strachan; Tamara J Stevenson; Briana Freshner; Matthew D Keefe; D Miranda Bowles; Joshua L Bonkowsky
Journal:  Hum Mol Genet       Date:  2017-09-15       Impact factor: 6.150

4.  Brain microsomal fatty acid elongation is increased in abcd1-deficient mouse during active myelination phase.

Authors:  Masashi Morita; Misato Kawamichi; Yusuke Shimura; Kosuke Kawaguchi; Shiro Watanabe; Tsuneo Imanaka
Journal:  Metab Brain Dis       Date:  2015-06-25       Impact factor: 3.584

Review 5.  Oxidative Stress in Patients with X-Linked Adrenoleukodystrophy.

Authors:  Marion Deon; Desirèe P Marchetti; Bruna Donida; Moacir Wajner; Carmen Vargas
Journal:  Cell Mol Neurobiol       Date:  2015-07-14       Impact factor: 5.046

6.  A Thyroid Hormone-Based Strategy for Correcting the Biochemical Abnormality in X-Linked Adrenoleukodystrophy.

Authors:  Meredith D Hartley; Lisa L Kirkemo; Tapasree Banerji; Thomas S Scanlan
Journal:  Endocrinology       Date:  2017-05-01       Impact factor: 4.736

7.  Oxidative Imbalance, Nitrative Stress, and Inflammation in C6 Glial Cells Exposed to Hexacosanoic Acid: Protective Effect of N-acetyl-L-cysteine, Trolox, and Rosuvastatin.

Authors:  Desirèe Padilha Marchetti; Luiza Steffens; Carlos E Jacques; Gilian B Guerreiro; Caroline P Mescka; Marion Deon; Daniella M de Coelho; Dinara J Moura; Alice G Viario; Fernanda Poletto; Adriana S Coitinho; Laura B Jardim; Carmen R Vargas
Journal:  Cell Mol Neurobiol       Date:  2018-10-09       Impact factor: 5.046

Review 8.  Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history.

Authors:  Stephan Kemp; Irene C Huffnagel; Gabor E Linthorst; Ronald J Wanders; Marc Engelen
Journal:  Nat Rev Endocrinol       Date:  2016-06-17       Impact factor: 43.330

Review 9.  Mammalian peroxisomal ABC transporters: from endogenous substrates to pathology and clinical significance.

Authors:  Stephan Kemp; Frederica L Theodoulou; Ronald J A Wanders
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

10.  Lipid alterations in human frontal cortex in ALS-FTLD-TDP43 proteinopathy spectrum are partly related to peroxisome impairment.

Authors:  Pol Andrés-Benito; Ellen Gelpi; Mariona Jové; Natalia Mota-Martorell; Èlia Obis; Manuel Portero-Otin; Mònica Povedano; Aurora Pujol; Reinald Pamplona; Isidro Ferrer
Journal:  Neuropathol Appl Neurobiol       Date:  2021-01-12       Impact factor: 8.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.